natgillin/translations-raw huggingface dataset:
If you have an infection with symptoms such as fever with a severely reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test.
Ako imate infekciju sa simptomima poput vrućice i jako pogoršanog općeg stanja ili vrućicu i simptome lokalne infekcije, poput boli u vratu, grlu ili ustima te otežanog mokrenja, morate se što prije obratiti liječniku kako bi se krvnim pretragama isključio nedostatak bijelih krvnih stanica (agranulocitoza).
• Tacrolimus (in cases of organ transplantation)
• Takrolimus (u slučaju presađivanja organa)
• Swelling of the feet and ankles.
• oticanje stopala ili gležnjeva
Nexium Control has a low likelihood of affecting your ability to drive or use machines.
Malo je vjerojatno da bi Nexium Control mogao utjecati na sposobnost upravljanja vozilima ili rukovanja strojevima.
Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.
U ispitivanjima u kojima se ocjenjivala istodobna primjena esomeprazola s naproksenom ili rofekoksibom nisu utvrđene klinički značajne farmakokinetičke interakcije tijekom kratkoročnih kliničkih ispitivanja.
The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired.
Metabolizam esomeprazola u bolesnika s blagim do umjerenim oštećenjem jetre može biti poremećen.
This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration.
To je povećanje ovisno o dozi, a nakon ponovljene primjene dovodi do povećanja AUC-a koje je veće od povećanja proporcionalnog dozi.
The major metabolites of esomeprazole have no effect on gastric acid secretion.
Glavni metaboliti esomeprazola ne utječu na lučenje želučane kiseline.
It is unknown whether esomeprazole/metabolites are excreted in human milk.
Nije poznato izlučuju li se esomeprazol/njegovi metaboliti u majčino mlijeko.
Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.
Preporučuje se nadzor kada se liječenje esomeprazolom započinje ili prekida istodobno s liječenjem varfarinom ili drugim kumarinskim derivatima.
• If you experience any of the symptoms detailed in Section 2 of this leaflet and it advises you to talk to your doctor or pharmacist.
• Ako osjetite bilo koje simptome opisane u dijelu 2. ove upute, za koje postoji napomena da se obratite liječniku ili ljekarniku.
For short-term treatment of reflux symptoms (heartburn, acid regurgitation) in adults, aged 18 or over.
Za kratkotrajno liječenje simptoma refluksa (žgaravice, vraćanje kiseline iz želuca) u odraslih u dobi od 18 godina ili više.
Approximately 78% of the subjects on 20 mg esomeprazole reported first resolution of heartburn within the first week of treatment compared to 52 - 58% for placebo.
Približno 78% ispitanika liječenih s 20 mg esomeprazola prijavilo je prvo povlačenje žgaravice unutar prvoga tjedna liječenja u usporedbi s 52-58% bolesnika koji su primali placebo.
You may also notice that when you lie down, that your heartburn gets worse.
Također možda primijetite pogoršanje žgaravice nakon što legnete.
• You get stomach pain or signs of indigestion such as nausea, fullness, bloating especially after food intake.
• Ako Vas boli želudac ili imate znakove probavnih smetnji, poput mučnine, osjećaja punoće ili nadutosti, osobito nakon unosa hrane.
• You have jaundice (yellowing of skin or eyes) or severe liver problems.
• Ako imate žuticu (koža ili oči postaju žuti) ili teške probleme s jetrom.
In two multicenter, randomized, double-blind, placebo-controlled pivotal studies 234 subjects with a recent history of frequent heartburn were treated with 20 mg esomeprazole for 4 weeks.
U dva multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana pivotalna ispitivanja, 234 ispitanika s nedavnim učestalim žgaravicama u anamnezi liječena su esomeprazolom u dozi od 20 mg tijekom 4 tjedna.
The investigators' assessments of heartburn resolution were consistent with the subjects' assessments, showing statistically significant differences between esomeprazole (34.7% - 41.8%) compared to placebo (8.0% - 11.4%).
Ispitivačeve procjene povlačenja žgaravice bile su dosljedne ispitanikovim procjenama pokazujući statistički značajne razlike između esomeprazola (34,7%-41,8%) u usporedbi s placebom (8,0%-11,4%).
Thus, when esomeprazole is combined with medicinal products metabolised by CYP2C19, such as warfarin, phenytoin, citalopram, imipramine, clomipramine, diazepam, etc., the plasma concentrations of these medicinal products may be increased and a dose reduction could be needed.
Stoga, kada se esomeprazol kombinira s lijekovima koji se metaboliziraju putem CYP2C19, kao što su varfarin, fenitoin, citalopram, imipramin, klomipramin, diazepam itd., može doći do povećanja plazmatske koncentracije navedenih lijekova te može biti potrebno smanjiti dozu navedenih lijekova.
Do not take this medicine if you are also taking a medicine containing nelfinavir (used to treat HIV infection).
Nemojte uzimati ovaj lijek ako također uzimate lijek koji sadrži nelfinavir (koristi se za liječenje HIV infekcije).
Česká republika Pfizer PFE, spol.
Česká republika Pfizer PFE, spol. s.r.o.
Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical study showed that coagulation times were within the accepted range.
U jednom je kliničkom ispitivanju istodobna primjena 40 mg esomeprazola u bolesnika liječenih varfarinom pokazala da su vremena koagulacije unutar prihvatljivoga raspona.
Common Uncommon Rare
Vrlo rijetko Nepoznato
As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.
Kao mjeru opreza treba izbjegavati istodobno uzimanje esomeprazola i klopidogrela.
In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.
U slučaju primjene visokih doza metotreksata možda će trebati razmotriti privremeni prekid liječenja esomeprazolom.
• Tacrolimus (in cases of organ transplantation).
• Takrolimus (u slučaju presađivanja organa).
Inconsistent data on the clinical implications of this PK/PD interaction in terms of major cardiovascular events have been reported from both observational and clinical studies.
I u opservacijskim i u kliničkim ispitivanjima prijavljeni su neujednačeni podaci o kliničkom značaju ove PK/PD interakcije u smislu ozbiljnih kardiovaskularnih događaja.
The glass should be rinsed with half a glass of water and the water drunk.
Čašu treba isprati s pola čaše vode, a zatim tu vodu popiti.
These findings have no implications for the posology of esomeprazole.
Ovi nalazi nemaju utjecaja na doziranje esomeprazola.
The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole.
Glavni dio metabolizma esomeprazola ovisi o polimorfno izraženom CYP2C19, koji je odgovoran za stvaranje hidroksi- i dezmetilnih metabolita esomeprazola.
• You lose a lot of weight for no reason.
• Ako bezrazložno gubite na tjelesnoj težini.
Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.
Rezultati ispitivanja u zdravih ispitanika pokazali su da postoji farmakokinetička (PK)/farmakodinamička (PD) interakcija između klopidogrela (udarna doza od 300 mg/doza održavanja od 75 mg na dan) i esomeprazola (40 mg peroralno na dan), koja smanjuje izloženost aktivnom metabolitu klopidogrela za prosječno 40%, a maksimalnu inhibiciju agregacije trombocita (potaknute ADP-om) smanjuje za prosječno 14%.
lansoprazole, rabeprazole or omeprazole).
lanzoprazol, rabeprazol ili omeprazol).
After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6-7 hours after dosing on day five.
Nakon višekratne primjene 20 mg esomeprazola jednom na dan tijekom pet dana, prosječne vršne vrijednosti lučenja kiseline nakon stimulacije pentagastrinom smanjile su se za 90%, mjereno petoga dana 6-7 sati nakon uzimanja doze.
The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.
Niže navedeni parametri većinom odražavaju farmakokinetiku u osoba u kojih je funkcionalan enzim CYP2C19, tj. koje su brzi metabolizatori.
• Feeling agitated, confused or depressed.
• uznemirenost, smetenost ili depresija
However, side effects such as dizziness and visual disturbances may uncommonly occur (see section 4).
Međutim, nuspojave poput omaglice i smetnji vida mogu se manje često javiti (pogledajte dio 4.).
Patients should not take Nexium Control as a long term preventive medicinal product.
Bolesnici ne smiju dugotrajno uzimati Nexium Control u preventivne svrhe.
Effects of other medicinal products on the pharmacokinetics of esomeprazole Medicinal products which inhibit CYP2C19 and/or CYP3A4
Učinci drugih lijekova na farmakokinetiku esomeprazola Lijekovi koji inhibiraju CYP2C19 i/ili CYP3A4
• Yellow skin, dark urine and tiredness, which can be symptoms of liver problems, seen rarely.
• žuta koža, tamna mokraća i umor, koji mogu biti simptomi jetrenih tegoba, javljaju se rijetko.
The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUCt by 280%.
Inhibitor CYP2C19 i CYP3A4, vorikonazol, povećao je AUCt omeprazola za 280%.
As a precautionary measure, you should preferably avoid the use of Nexium Control during pregnancy.
Kao mjera opreza, trebali biste izbjegavati primjenu lijeka Nexium Control tijekom trudnoće.
Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours.
Povišena koncentracija kromogranina A (CgA) može utjecati na pretrage za neuroendokrine tumore.
What you need to know before you take Nexium Control
Što morate znati prije nego počnete uzimati Nexium Control
The area under the plasma concentration-time curve increases with repeated administration of esomeprazole.
Površina ispod krivulje koncentracija-vrijeme u plazmi povećava se s ponovljenom primjenom esomeprazola.
Immune system disorders hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock
Poremećaji imunološkog sustava reakcije preosjetljivosti, npr. vrućica, angioedem i anafilaktička reakcija/šok
If you take more Nexium Control than you should If you take more Nexium Control than recommended, talk to your doctor or pharmacist straight away.
Ako uzmete više lijeka Nexium Control od preporučenog, odmah se obratite svom liječniku ili ljekarniku.
A dose adjustment of esomeprazole is not regularly required in either of these situations.
Niti u jednom od tih slučajeva obično nije potrebno prilagođavati dozu esomeprazola.
• You have been taking treatment continuously for reflux or heartburn for 4 or more weeks.
• Ako uzimate lijekove za refluks ili žgaravicu neprekidno 4 tjedna ili dulje.
After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour.
Nakon peroralne primjene 20 mg ili 40 mg esomeprazola djelovanje započinje unutar jednoga sata.
Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin and quinidine.
Pokazalo se da esomeprazol nema klinički značajnih učinaka na farmakokinetiku amoksicilina ni kinidina.
Nexium Control is available in a pack size of 14 gastro-resistant hard capsules in high-density polyethylene (HDPE) bottles with an induction seal closure and child resistant closure.
Nexium Control dostupan je u pakiranju od 14 želučanootpornih tvrdih kapsula u bočicama od polietilena visoke gustoće (HDPE) sa zaštitnom folijom na otvoru i sigurnosnim zatvaračem za djecu.
You must talk to a doctor if you do not feel better or if you feel worse after 14 days.
Obavezno se obratite liječniku ako se ne osjećate bolje ili ako se osjećate lošije nakon 14 dana.
Hepatobiliary disorders increased liver enzymes hepatitis with or without jaundice hepatic failure, hepatic encephalopathy in patients with pre-existing liver disease
Poremećaji jetre i žuči povišene vrijednosti jetrenih enzima hepatitis sa žuticom ili bez nje zatajenje jetre, hepatička encefalopatija u bolesnika s postojećom bolešću jetre
Adverse reactions such as dizziness and visual disturbances are uncommon (see section 4.8).
Nuspojave poput omaglice i smetnji vida javljaju se manje često (vidjeti dio 4.8).
Esomeprazole is extensively plasma protein bound and is therefore not readily dialysable.
Esomeprazol se u velikoj mjeri veže na proteine u plazmi pa se stoga teško uklanja dijalizom.
Esomeprazole should not be used during breast-feeding.
Esomeprazol se ne smije primjenjivati tijekom dojenja.
• Low numbers of red blood cells, white blood cells, and platelets (a condition called pancytopenia)
• nizak broj crvenih i bijelih krvnih stanica te krvnih pločica (stanje koje se naziva pancitopenijom)
Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile (see section 5.1).
Liječenje inhibitorima protonske pumpe može dovesti do blago povećanog rizika od gastrointestinalnih infekcija, poput infekcija bakterijama Salmonella i Campylobacter, a u hospitaliziranih bolesnika i do moguće infekcije s Clostridium difficile (vidjeti dio 5.1).
As a precautionary measure, it is preferable to avoid the use of Nexium Control during pregnancy.
Kao mjera opreza, preporučuje se izbjegavati primjenu lijeka Nexium Control tijekom trudnoće.
High-density polyethylene (HDPE) bottle with an induction seal closure and child resistant closure containing 14 gastro-resistant capsules.
Bočica od polietilena visoke gustoće (engl. high-density polyethylene, HDPE) sa zaštitnom folijom na otvoru i sigurnosnim zatvaračem za djecu koja sadrži 14 želučanootpornih kapsula.
The investigators also found esomeprazole to be significantly more effective than placebo in resolving acid regurgitation (58.5% - 63.6% vs placebo 28.3% - 37.4%) during the week 2 evaluation.
Ispitivači su također pronašli da je esomeprazol značajno djelotvorniji od placeba u liječenju regurgitacije kiseline (58,5%-63,6% u odnosu na 28,3%-37,4% u bolesnika koji su primali placebo) tijekom procjene u 2. tjednu.
If you forget to take Nexium Control
Ako ste zaboravili uzeti Nexium Control
(Cyprus Pharmaceutical Organization Ltd.)
Pfizer Ελλάς Α.Ε. (Cyprus Pharmaceutical Organization Ltd.)
Other secondary endpoints were supportive of the primary endpoint, including relief of heartburn at week 1 and week 2, percentage of 24 hour days without heartburn at week 1 and week 2, mean heartburn severity at week 1 and week 2, and time to initial and sustained resolution of heartburn over a 24 hour period and during the night compared to placebo.
Druge sekundarne mjere ishoda podržavale su primarne, uključujući osjećaj olakšanja bez žgaravice u 1. tjednu i 2. tjednu, te postotak 24-satnih dana bez žgaravice u 1. tjednu i 2. tjednu, prosječnu težinu žgaravice u 1. tjednu i 2. tjednu i vrijeme do početnog i održanog povlačenja žgaravice tijekom razdoblja od 24 sata te tijekom noći, u usporedbi s placebom.
After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers).
Nakon višekratne primjene doze od 40 mg esomeprazola jedanput na dan prosječna vrijednost površine ispod krivulje bila je otprilike 100% veća u sporih metabolizatora nego u ispitanika u kojih je enzim CYP2C19 funkcionalan (brzi metabolizatori).
• You may need to take the capsules for 2 or 3 days in a row before your reflux symptoms (for example, heartburn and acid regurgitation) get better.
• Kapsule ćete možda morati uzimati 2 ili 3 dana zaredom prije nego što osjetite poboljšanje simptoma refluksa (primjerice, žgaravice i povrata želučane kiseline).
Pack sizes of 7 and 14 gastro-resistant tablets.
Veličine pakiranja: 7 i 14 želučanootpornih tableta.
• They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis.
• u slučaju značajnog neplaniranog gubitka težine, opetovanog povraćanja, disfagije, hematemeze ili melene te kod sumnje na želučani ulkus ili postojanja želučanog ulkusa, potrebno je isključiti maligne bolesti, jer liječenje esomeprazolom može ublažiti simptome i odgoditi postavljanje dijagnoze.
• Low levels of sodium in the blood.
• niske razine natrija u krvi.
• Cilostazol (used to treat intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and difficulty in walking).
• Cilostazol (koristi se za liječenje intermitentne klaudikacije - stanja u kojem nedostatna opskrba krvlju mišića nogu uzrokuje bol u nogama i probleme pri hodanju).
Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.
Istraživanja na životinjama u kojima se ispitivala peroralno primijenjena racemična smjesa omeprazola nisu ukazala na učinke povezane s plodnošću.
A light pink, oblong, biconvex, film-coated, gastro-resistant tablet of 14 mm x 7 mm engraved with ‘20 mG' on one side and ‘A/EH' on the other side.
Svijetloružičasta, duguljasta, bikonveksna, filmom obložena, želučanootporna tableta veličine 14 mm x 7 mm s utisnutom oznakom „20 mG“ na jednoj i „A/EH“ na drugoj strani.
Following a single dose of 40 mg esomeprazole the mean are under the plasma concentration-time curve is approximately 30% higher in females than in males.
Nakon jednokratne doze od 40 mg esomeprazola prosječna vrijednost površine ispod krivulje je približno 30% veća u žena nego u muškaraca.
• The active substance is esomeprazole.
• Djelatna tvar je esomeprazol.
• Dizziness, tingling feelings such as “pins and needles”.
• omaglica, osjećaj trnaca „poput bockanja iglicama“
For 20 mg esomeprazole the corresponding values are 50% and 68% respectively.
Za dozu od 20 mg esomeprazola odgovarajuće vrijednosti bioraspoloživosti su 50% odnosno 68%.
What can I do to help relieve my symptoms?
Kako možete olakšati simptome žgaravice?
Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients.
Istodobna primjena 40 mg esomeprazola povećala je za 13% najnižu koncentraciju fenitoina u plazmi u bolesnika s epilepsijom.
Do not take Nexium Control
Nemojte uzimati Nexium Control
• Cilostazol (used to treat intermittent claudication - a condition where poor blood supply to the leg muscles causes pain and difficulty in walking)
• Cilostazol (koristi se za liječenje intermitentne klaudikacije - stanja u kojem nedostatna opskrba krvlju mišića nogu uzrokuje bol u nogama i probleme pri hodanju)
This can cause weakness, bruising, or make infections more likely.
To može uzrokovati slabost i stvaranje modrica ili povećati sklonost infekcijama.
• Effects on your stomach or gut: diarrhoea, stomach ache, constipation, wind (flatulence).
• učinci na želudac ili crijeva: proljev, bol u želucu, zatvor, vjetrovi (flatulencija)
Nexium Control is not meant to bring immediate relief.
Nexium Control nije namijenjen za trenutačno ublažavanje simptoma.
Your doctor may need to monitor you when you start or stop taking Nexium Control.
Liječnik će Vas možda morati nadzirati kada započnete ili prekinete liječenje lijekom Nexium Control.
Excipient(s) with known effect Each gastro-resistant tablet contains 28 mg sucrose.
Pomoćna(e) tvar(i) s poznatim učinkom Jedna želučanootporna tableta sadrži 28 mg saharoze.
• You may need to take the tablets for 2 or 3 days in a row before your reflux symptoms (for example, heartburn and acid regurgitation) get better.
• Tablete ćete možda morati uzimati 2 ili 3 dana zaredom prije nego što osjetite poboljšanje simptoma refluksa (primjerice, žgaravice i povrata želučane kiseline).
Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUCτ by 15% and 41%, respectively.
Omeprazol (u dozi od 40 mg jedanput na dan) je povećao Cmax vorikonazola (supstrata CYP2C19) za 15%, a njegov AUCτ za 41%.
The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d.
Farmakokinetika esomeprazola ispitivana je u dozama do 40 mg dvaput na dan.
• Digoxin (used for heart problems)
• Digoksin (koristi se za srčane tegobe)
Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme.
Esomeprazol inhibira CYP2C19, glavni enzim koji metabolizira esomeprazol.
• Digoxin (used for heart problems).
• Digoksin (koristi se za srčane tegobe).
Capsule approximately 11 x 5 mm, with a clear body, and an amethyst cap imprinted with “NEXIUM 20 MG” in white.
Kapsula veličine približno 11 x 5 mm sa prozirnim tijelom i ljubičastom kapicom na kojoj je bijelom tintom otisnuto “NEXIUM 20 MG”.
Medicinal products known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John's wort (Hypericum perforatum)) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.
Lijekovi za koje se zna da induciraju CYP2C19, CYP3A4 ili oba izoenzima (poput rifampicina i gospine trave (Hypericum perforatum)) mogu povećati metabolizam esomeprazola i tako smanjiti njegovu koncentraciju u serumu.
In a study in healthy subjects, there was a decreased exposure by almost 40% of the active metabolite of clopidogrel when a fixed dose combination of esomeprazole 20 mg + acetylsalicylic acid 81 mg was given with clopidogrel compared to clopidogrel alone.
U ispitivanju u zdravih ispitanika primijećeno je smanjenje izloženosti aktivnom metabolitu klopidogrela od gotovo 40% kada se uz klopidogrel davala fiksna kombinacija 20 mg esomeprazola + 81 mg acetilsalicilne kiseline u usporedbi s primjenom samo klopidogrela.
Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.
Istodobna primjena 30 mg esomeprazola uzrokovala je 45% manji klirens diazepama, supstrata CYP2C19.
Reproductive system and breast disorders gynaecomastia
Poremećaji reproduktivnog sustava i dojki ginekomastija
Blood and lymphatic system disorders leukopenia, thrombocytopenia agranulocytosis, pancytopenia
Poremećaji krvi i limfnog sustava leukopenija, trombocitopenija agranulocitoza pancitopenija
Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids.
Ispitivanja kancerogenosti na štakorima uz primjenu racemične smjese ukazala su na hiperplaziju želučanih stanica nalik na enterokromafine stanice i karcinoide.
Esomeprazole must not be used concomitantly with nelfinavir (see section 4.5).
Esomeprazol se ne smije primjenjivati istodobno s nelfinavirom (vidjeti dio 4.5).
Nervous system disorders headache dizziness, paraesthesia, somnolence taste disturbance
Poremećaji živčanog sustava glavobolja omaglica, parestezije, somnolencija poremećaj okusa
You may experience symptoms such as diarrhoea, stomach ache, constipation, feeling or being sick and weakness.
Mogli biste osjetiti simptome (kao što su proljev, bol u želucu, zatvor, mučnina ili povraćanje) i slabost.